The risk of carcinoma developing in OC users is very difficult to assess. An eightfold increase in risk has been suggested, but the spontaneous incidence is so low that even this does not represent a significant level.
With the exception of the OC users, the chance of a hepatocellular carcinoma arising in a noncirrhotic liver is extremely small. The real frequency of tumours in cirrhotic livers is probably underestimated for two reasons. Firstly, in many of the countries with a high incidence of liver tumours, postmortem examinations are rarely carried out so that the exact relationship between cirrhosis and carcinoma cannot be determined. Secondly, it is easy to miss small nodules of tumour in a highly nodular cirrhotic liver seen at necropsy. Histologically a reticulin stain is helpful, because reticulin is sparse or absent in areas of neoplasia but copious in cirrhotic liver. In patients with haemochromatosis, the tumour cells are unable to synthesize haemosiderin and therefore the tumour nodules will stain negatively for iron. Clinically, the development of tumour in a cirrhotic liver can be detected by a rise in the serum alphafetoprotein (a-FP) level.
Response to chemotherapy can also be monitored by measuring a-FP.
In summary, despite broad similarities between species as diverse as fish and man in terms of structure, function and metabolism and consequently in their susceptibility to infectious and toxic agents, apparently quite minor species differences result in considerable difficulty in interspecies extrapolation. However, animals may still serve as useful models of human disease, for example viral hepatitis in the woodchuck, and are an essential part of safety evaluation studies for drugs and chemicals. Caution must be exercised in interpretation of the results, particularly in the field of carcinogenesis. 
